Can-Fite BioPharma Files 6-K, Incorporates Press Release
Ticker: CANF · Form: 6-K · Filed: Dec 4, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, sec, registration
TL;DR
Can-Fite BioPharma filed a 6-K, incorporating a press release into its SEC filings. Check Exhibit 99.1 for details.
AI Summary
Can-Fite BioPharma Ltd. filed a Form 6-K on December 4, 2024, to report information for the month of December 2024. The filing incorporates by reference a press release (Exhibit 99.1) into its existing Registration Statements on Form S-8 and Form F-3. This action is standard procedure for updating ongoing filings with new information.
Why It Matters
This filing indicates that Can-Fite BioPharma is providing updated information to the SEC, which may contain material developments relevant to investors.
Risk Assessment
Risk Level: low — A Form 6-K is typically an informational filing and does not inherently signal significant risk unless the incorporated press release contains negative news.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Registrant
- 0001213900-24-105237 (filing_id) — Accession Number
- 20241204 (date) — Filing Date
- Exhibit 99.1 (document) — Incorporated Press Release
- Form S-8 (filing_type) — Registration Statement
- Form F-3 (filing_type) — Registration Statement
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report information for the month of December 2024 and to incorporate by reference a press release (Exhibit 99.1) into the registrant's existing Registration Statements on Form S-8 and Form F-3.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on December 4, 2024.
What is the exact name of the company filing this report?
The exact name of the company is Can-Fite BioPharma Ltd.
Which SEC registration statements are being updated by this filing?
This filing updates Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384, and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000, and 333-281872).
What is the address of Can-Fite BioPharma's principal executive offices?
The address of Can-Fite BioPharma's principal executive offices is 26 Ben Gurion Street, Ramat Gan, 5257346, Israel.
Filing Stats: 277 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-12-04 07:05:10
Filing Documents
- ea0223578-6k_canfite.htm (6-K) — 11KB
- ea022357801ex99-1_canfite.htm (EX-99.1) — 13KB
- 0001213900-24-105237.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 4, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 3